Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
AMT-676 by Multitude therapeutics for Neuroendocrine Tumors: Likelihood of Approval
AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Neuroendocrine Tumors. According to GlobalData, Phase...
Data Insights
AMT-676 by Multitude therapeutics for Pancreatic Ductal Carcinoma: Likelihood of Approval
AMT-676 is under clinical development by Multitude therapeutics and currently in Phase I for Pancreatic Ductal Carcinoma. According to GlobalData,...